CDK2 and melanoma: In anti-melanomas compounds, we have demonstrated that alternol could decrease the expression levels of cyclin-dependent kinase 2 (CDK2) and proliferating cell nuclear antigen (PCNA), and activate CDK inhibitor1A (p21) to inhibit melanoma B16F0 cell proliferation5.